SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3999A solid Reason that NVS will try to BUY ARIA bloomberg.comcivic08801-12/4/2015
3998 It is remarkable that we were able to command milestone payments from a Big Phatktom-11/28/2015
3997Interview with Ariad GM of France, Olivier Polley... Highlight: [In the next fejaybe111/28/2015
3996effective...irrespective of baseline mutation status. Does Pona work in HCV? :-)DewDiligence_on_SI-11/25/2015
3995New article on resistance to ponatinib in Blood... "No single or compound jaybe-11/24/2015
3994Could be, but then compare with patent language below for pona or briga. Why spjaybe-11/24/2015
3993"Less than about a picomolar" IC50 sounds to me patent-talk to cover amulanoon2007-11/24/2015
3992Found it - we of course don't know if the particular lead they have selectedBiomaven-11/24/2015
3991>> "less than 1 picomolar" IC50s I haven't had a chance to Biomaven-11/24/2015
3990Initially '788 will have little overlap with osimertinib, about 5-6% represejaybe111/23/2015
3989Just checked the patent, AP32788 is a me too of AZD9291, likely to have a comparmedichem-11/23/2015
3988So how big is the market potential for AP32788? Although the patent refers to jaybe411/19/2015
3987Thanks for finding that. Link is here - yours didn't work: patentscope.wipBiomaven111/19/2015
3986AP32788 patent publishes...and the compound is... A next-gen pan-EGFR inhibitorjaybe111/19/2015
3985Good news for all ALK inhibitors... Especially more potent 2nd gen inhibitors wjaybe-11/18/2015
3984NantOmics finds pona response in triple-negative breast cancer... Not clear of jaybe-11/14/2015
3983AZD9291 beats rociletinib in the race to the T790M lung cancer market And so thtktom-11/13/2015
3982FGFR1 is essential, doubtful either of those will have meaningful activity in FGjaybe-11/10/2015
3981Other TKIs that inhibit FGFR, PDGFR and VEGFR in clinical development for advancmulanoon2007-11/10/2015
3980Article in 'Oncogene' hints at pona activity in FGFR1 squamous cell lungjaybe-11/9/2015
3979Correct, standard part of IP moat concerning formulations of pona. [More than yjaybe-11/9/2015
3978I think that's just ponatinib or some version of it.Biomaven-11/9/2015
3977Jaybe, this could be the answer: globalipnews.comtktom-11/9/2015
3976Although a next-gen, pan-EGFR inhibitor could address the EGFR TKI frontline marjaybe-11/4/2015
3975You have to be realistic about the value of any pre-clinical drug in this class.Biomaven111/4/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News